|Vaccination Liberation - Information|
Ingredients of Vaccines
Artificially Sweetened Times
Books Videos Tapes
100+ Anti-Vax links
FluMist®: Links and articles
Flumist Vaccine http://www.hpathy.com/health/barb_flumistvaccine.asp -- by Barbara M.
The Flumist vaccine is a live virus vaccine that is given as a nasal spray. The virus can be shed from the nasal passages of a vaccinated individual for up to 21 days after vaccination. The package insert for the Flumist vaccine clearly states "Due to the possible transmission of vaccine virus, Flumist recipients should avoid being in close (for example, within the same household) contact with immunocompromised individuals for 3 weeks following vaccination."
The description of "Close contact" apparently does not apply to schools. Thousands of children are being vaccinated with this live vaccine with no regard to who may be in their class, who they may be interacting with, sitting next to, playing with, eating with, etc. Children are free to get the vaccine and head to school, where they will spend a good 7 to 8 hours sitting in the same room, possibly right next to an immune suppressed child. How many children have asthma, eczema, diabetes, are on corticosteriods, have kidney dysfunction and reactive airway disease? How many immune suppressed individuals are being exposed to the virus from recently vaccinated individuals? Who will be held responsible if an immune suppressed child becomes ill from being in contact with a recently vaccinated individual? Will it be MedImmune/Wyeth, the manufacturer of Flumist? The pediatricians? The school? The parents? Who?
More medical experimentation at school.
Total misunderstanding and misrepresentation of facts:
Mandatory flu vaccination in Japan did not work and thus the mandatory law was recinded. Yet the worthless flu vaccination program is being offered as evidence that flu vaccines save lives. http://knoxcounty.org/health/pdf/flumist_japan_article.pdf
[List of University Hospitals which are engaged in vaccine 'research' are at the end of the above page.]
this web page lists a series of press releases over several years. http://www.prnewswire.com/gh/cnoc/comp/114000.html
During the 2003 flu season, the flu caused nearly 152 deaths from 40 states in children younger than 18 years of age. Even more surprising, many of these children were considered to be generally healthy, with no high-risk medical conditions.
[The above is obviously the "pro-vaccine sales" position. There is even a 'game' on their site where the object is to vaccinate as many children as possible in a short period of time.]
(statement from the AAP)
On June 17, 2003 the Food and Drug Administration (FDA) approved the use of FluMist, an influenza vaccine that is the first nasally administered vaccine to be marketed in the United States. It is also the first live virus influenza vaccine approved in the U.S.
FluMist is approved to prevent influenza illness due to influenza A and B viruses in healthy children and adolescents, ages 5-17 years, and healthy adults, ages 18-49. In clinical trials, FluMist was evaluated in 20,228 individuals, including over 10,000 healthy children 5-17 years old. The efficacy of the vaccine in preventing influenza was approximately 87 percent among children included in the trial. In healthy adults ages 18-49 years, FluMist was effective in reducing severe illnesses with fever, and upper respiratory problems which may be caused by influenza infection.
F.D.A. Approval Of Nasal Vaccine For Flu Expected http://query.nytimes.com/gst/health/article- page.html?res=950DE0D6143AF93AA25757C0A9659C8B63
By ANDREW POLLACK
Published: April 19, 2003
''This is not a breakthrough new therapy for a life-threatening disease,'' he said. ''It's a flu vaccine with a different delivery mechanism.'' The absence of approval for children under 5 would limit the market, he said, adding, ''Their best calling card was to pediatricians.'' The project was rescued in 1995 by Aviron, a young California biotechnology company. In 1999, Wyeth, having grown more interested in vaccines, became involved again, paying Aviron several hundred million dollars for rights to the vaccine it had abandoned a few years earlier.
Aviron was acquired by MedImmune in early 2002 for $1.6 billion.
MedImmune will have to race to prepare a new vaccine to match the strains of influenza that are prevalent each year, crossing its three master strains of attenuated, cold-tolerant viruses with the three wild strains chosen to be in that year's vaccine. The company will have to test each new vaccine in 300 healthy volunteers to make sure the vaccine is not virulent.
Other nasal flu vaccines are also on the horizon. ID Biomedical of Vancouver, British Columbia, is developing one using a killed virus that it hopes to have on the market as early as 2006. Biodiem of Australia is working on a live nasal vaccine similar to one now used in Russia.
FluMist (ind. 1) Aviron PLA submitted 06/98
FluMist (ind. 2) Aviron Phase II Entered 09/97
FluMist (ind. 3) Aviron PLA/NDA filed 08/98
FluMist (ind. 4) Aviron Phase III Entered 09/97
FluMist (ind. 5) Aviron Entered Phase III 09/97
FluMist (ind. 6) Aviron PLA/NDA filed
FluMist (ind. 7) Aviron PLA/NDA filed
Pep talk given to US house of reps http://energycommerce.house.gov/108/Hearings /11182004hearing1404/Coelingh2260.htm
The Committee on Energy and Commerce
Ms. Kathleen Coelingh
Flu Vaccine: Protecting High-Risk Individuals and Strengthening the Market
Good morning. My name is Dr. Kathleen Coelingh, and I am the Senior Director of Regulatory and Scientific Affairs at MedImmune, Inc, a Maryland-based biotechnology company that manufactures the innovative intranasal influenza vaccine, FluMist. Approved by the FDA last year for healthy persons 5 to 49 years of age, FluMist is the first advancement in influenza prevention in 50 years.
We are at a critical juncture in defining what the influenza vaccine market will look like in the future and how U.S. based vaccine manufacturers will meet the needs of this country going forward. What will be the incentives for companies to build U.S. based manufacturing facilities? How will our government drive vaccine acceptance, utilization, and demand — since it is demand that ultimately determines the supply of vaccine manufactured? And what will be the incentive for continued innovation?
MedImmune recommends that this committee support and encourage two key longer-term solutions in the realm of policy changes and incentives for innovation. The first recommendation is to move towards adoption of a universal recommendation for influenza vaccine for all Americans. The current recommendations, which are based on age groups and an ever-expanding list of underlying chronic medical conditions, are both complicated for the health care provider and confusing to the public. We believe that a universal recommendation will stabilize demand for vaccine, thereby leading to increased vaccine supply, and ultimately to substantially lowering the current morbidity and mortality rates.
As an interim step, MedImmune recommends required vaccination of school-aged children, who have a very high influenza attack rate and spread influenza to younger siblings, parents, grandparents, etc. Thus, vaccination of school children would directly benefit the children themselves and may also have the potential to greatly reduce the impact of influenza in our communities. This concept of protecting an entire community by vaccinating the school-aged children has been demonstrated in Japan and in studies in the U.S. In conjunction with this interim step, money must be appropriated to expand the education of the public and the medical community about the seriousness of influenza and the value of influenza prevention.
The second solution that MedImmune recommends to ensure continued influenza vaccine supply is to provide tax incentives for scientific innovation and for construction of U.S. based facilities. MedImmune is a primary innovator in the area of molecular techniques, termed "reverse genetics." The use of reverse genetics is vital to producing seeds for an H5N1 pandemic vaccine. MedImmune owns multiple patents in this area and has granted free access to its reverse genetics intellectual property to government organizations and to other companies developing pandemic influenza vaccines. MedImmune is currently collaborating with the National Institutes of Health to produce intranasal pandemic vaccines and to test them in clinical trials.
MedImmune also has core expertise in the innovative area of cell culture manufacturing. The main advantages of manufacturing using cell culture are elimination of dependence on egg supplies and more consistent and rapid production, which will be critical in the event that the egg supply is decimated by the emergence of a pandemic virus. The transition from egg-based to cell-based manufacturing will require considerable investment in the construction of new manufacturing facilities and clinical studies. Tax incentives to subsidize the cost of such innovations are necessary to guarantee a more stable vaccine supply on a yearly basis and when the pandemic arrives.
The government also needs to incentivize manufacturers to build manufacturing facilities in the U.S. There is an increased risk that with offshore manufacturing, companies will face political decisions that may prevent product from entering the U.S. — particularly in the event of a catastrophic pandemic. Tax incentives for U.S.-based manufacturing facilities would encourage manufacturers to build more facilities in the U.S.
To address what MedImmune has done during the current vaccine shortage, since October 5th, we have worked diligently with the appropriate authorities to:
1. Blend and fill our excess bulk vaccine to produce an additional 2 million doses of FluMist, bringing total production this year to about 3 million doses;
Shifting gears a bit and looking ahead to next season, you must understand that the influenza vaccine manufacturing campaign for the 2005-2006 season is starting right now. We are already preparing the new vaccine seeds for strains anticipated to be in next year's vaccine and making decisions about how many doses of vaccine we will manufacture next year, including deciding how many eggs to order. Thus, the amount of FluMist that will be available for next year will soon be finalized.
With some prompt, additional regulatory cooperation, MedImmune has the capacity to produce between 8 and 10 million doses next season. These regulatory actions include:
1. FDA approval allowing for the production of larger lot sizes and product filtration;
To summarize, MedImmune is clearly at a crossroads in determining not only how much FluMist will be available next season, but also whether our investments in innovation will be recouped in this market. Our level of production for next season depends upon the occurrence of several immediate regulatory actions. But whether MedImmune expands its production and whether companies continue their efforts to develop influenza vaccines depends in large part upon the government's commitment to encouraging innovation and driving demand. Requiring childhood flu vaccinations as an interim step towards a universal recommendation and legislating tax incentives for both scientific innovation and U.S.-based manufacturing will go a long way towards stabilizing and ensuring an adequate supply of influenza vaccine in the near future.
The Committee on Energy and Commerce
CIDRAP to participate in nasal flu vaccine study
The Minnesota portion of the study will be conducted in St. Cloud next school year (2004-05). Drs. Moore and McClure anticipate enrolling nine elementary schools. FluMist vaccine will be offered free-of-charge in the school setting to children in three "target" schools, and the remaining six schools will serve as "control" schools (where vaccine will not be offered free in the school setting).
Information on illness rates among school children and their family members will be collected during the peak of the influenza season. The rates in the target and control schools will be compared. In addition, school absenteeism rates will be monitored in all participating schools during the entire school year.
The overall goal of the study is to determine whether giving FluMist in the school setting can reduce school absenteeism rates and/or illness rates in family members during the annual influenza season. Addressing this question will provide important public health information and will be used to inform national childhood influenza vaccination policies.
The study is sponsored by MedImmune, maker of FluMist vaccine.
2004 Sept 05
http://miva.sctimes.com/miva/cgi-bin/miva? Education/index.mv+read+ healthstories+2004090519505344
Area students invited to join FluMist study
Some parents in the St. Cloud school district should receive information in the mail this week about a national study their children can join.
The study involves FluMist, a nasal spray that contains influenza vaccine. The University of Minnesota and the local school district are working on the voluntary study. Students in Oak Hill, Lincoln and Clearview elementary schools are eligible to participate.
Students at Westwood, Discovery and Kennedy elementary schools will serve as the control groups.
The goal is to enroll as many healthy students in the study as possible, said Dr. Elizabeth McClure, research associate for the university's Center for Infectious Disease Research and Policy. It's free to participate.
FluMist has been approved for use for about two years. The study is intended to see if having a large number of students vaccinated makes a difference in the community's number of flu cases. The study is not intended to confirm the nasal spray is effective, McClure stressed.
The thought behind vaccinating children en masse is that it will lessen the number of flu cases in a community because children have the flu more often than adults and pass it to peers, McClure said.
A similar study done in Maryland showed FluMist had a significant effect on student absences, McClure said. Illness among family members and the amount of work time taken off by parents to take care of sick children dropped.
June Spanier, a parent of a fourth-grader at Oak Hill Community School, said she definitely wants her daughter to participate. Many parents seem enthusiastic about the study, she said.
"I don't think any child loves shots," she said. "If this were an alternative, I think they would probably choose this."
FluMist is approved for healthy people aged 5 to 49. It's not safe for some people, including those with asthma and immune deficiency diseases.
Besides St. Cloud, FluMist studies will be done in schools in Washington, Texas and Maryland.
[One school had a lower number of flu cases than another school and this "Proves?" FluMist is effective???????]
Study finds FluMist effective, cost-effective
Sales of Gaithersburg-based MedImmune's FluMist flu vaccine may have been disappointing this year, but a new study from the University of Maryland School of Medicine says the drug has some strong benefits -- and not just in preventing the flu.
According to the study -- funded by MedImmune -- families of school children who received FluMist during an in-school immunization program experienced a significant drop in several common medical and economic consequences of the flu. The study found a 72 percent reduction in lost workdays for parents and a 50 percent drop in the purchase of prescription drugs, herbal medicines and over-the-counter flu remedies.
Dr. James King, a pediatrician at the University of Maryland Medical Center and lead investigator for the study, said he "never expected such a tremendous impact on the families" who received FluMist. But he said the impact made "biologic sense," because children are most susceptible to flu. Stopping the flu in children can then reduce its impact in the larger community, he said.
For the study, 39 percent of the students at Elmer A. Wolfe Elementary School in Union Bridge were vaccinated between November and January, with a total of 185 students receiving FluMist. Researchers then compared the flu-season experiences of the families at Union Bridge with two other schools without vaccination programs.
The Elmer Wolfe families saw a 72 percent drop in workdays lost, 46 percent drop in school days lost, a 67 percent decline in medical visits for adults and a 60 percent decline for children. Absenteeism at Elmer Wolfe was just 4.4 percent lower than the other schools, but researchers said that was likely because 61 percent of students at the school did not receive the vaccine.
King also said FluMist performed well even though it was administered just as a flu outbreak was hitting the community.
Researchers plan to expand the study in the fall, with FluMist to be distributed in schools in Minnesota, Washington, Texas and three schools in Carroll County.
MedImmune earlier this month told investors that it would consider cutting the price of FluMist in hopes of boosting sales. Of MedImmune's $489 million in first-quarter revenue, just $31 million came from FluMist sales.
.. and the New York Times also reports that F.D.A. Approval of Nasal Vaccine for Flu Expected.
Flumist - developed at the University of Michigan - and to be sold by MedImmunie - will be indicated for people 5 to 50 years old.
Yes .. you heard that right. The populations for whom influenza vaccine is reccomended are the populations for whom Flumist is not indicated.
It'll also cost much more.
Flu Vaccines For All Americans by 2006
Not only are Americans paying for and swallowing almost half of all pharmaceutical drugs sold world wide - $ 230 billion worth out of a total of 500 billion - leading to a rise of 11 % last year in US drugs spending, in the future all Americans without exception are to be asked to "get their flu shot" every year. This is the scenario that's being deliberated by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control in Atlanta, writes Mark Sircus in his Medical News Commentaries.
Reading this excellent summary of Sircus, it would seem time for Americans to start considering the implications of a "public health policy" that is being foisted upon them by the pharmaceutical industry through the state's institutions...
Medical News - March 17, 2004
Advisory Committee on Immunization Practices
An advisory group to the federal government is considering recommending that all Americans receive annual flu vaccinations, a step that would result in the largest vaccination enterprise in United States history. The Advisory Committee on Immunization Practices (ACIP) is a group of people in the background of the Center for Disease Control (CDC) making recommendations on what federal health policy should be at the CDC. Staffers of both the FDA and the CDC are known for their close financial and working ties with the pharmaceutical people and conflict of interest is a real problem in both of these agencies, a problem being raised in congressional hearings but one getting regularly swept under the carpet.
The Advisory Committee on Immunization Practices is something else again for they represent the very heart and soul of pharmaceutical companies. They are every parent's worst nightmare and there are no polite words to describe their true intentions though some like Doctor John Martin, a scientist well familiar with the inner circles at the FDA and the CDC says, "My reaction to the members of the ACIP that I have met personally is that they first avoid any criticism of their own actions. Second, they work towards the interest of vaccine manufacturers in the sincere belief that vaccines are good."
It is not in the financial interests of the pharmaceutical industry to prevent common diseases because the maintenance and expansion of diseases is a prerequisite for the financial health of this industry. It does not take a full medical education to understand that these people are not interested in the public's health. The pharmaceutical industry is an investment industry driven by profits so improving human health is not the driving motivating force of these people. The same investment groups that control the global petrochemical and chemical industries strategically developed the pharmaceutical investment industry over an entire century. They are poised for a massive assault on everyone's body including that of your children for they would add another shot to be received each year, starting for babies of six months of age.
The implications are staggering. This news is not surprising, though, because "It's a direction toward which the ACIP has been moving in the past few years in terms of broadening its recommendations for who should get vaccinated," says Keiji Fukuda, an epidemiologist at the CDC in Atlanta. Best-selling author John Le Carré stated, "Big Pharma [the industry in general] is engaged in the deliberate seduction of the medical profession, country by country, worldwide. It is spending a fortune on influencing, hiring and purchasing academic judgment to a point where, in a few years' time, if Big Pharma continues unchecked on its present happy path, un-bought medical opinion will be hard to find." The ACIP succeeded in getting the Hepatitis B vaccine on the universal list demonstrating this seduction by adding a highly dangerous 'unnecessary' vaccine administered starting from the first day of life. Now they want to add another one in an even more universal vaccination campaign.
For several years now newspapers around the world have threatened the public with graphic accounts of a flu plague that was destined to kill. A perfect example of the hysteria that has been deliberately introduced in the public's mind appeared in The Sunday Mirror in England back in September of 1997: "MILLIONS AT RISK FROM KILLER FLU - Doctors are preparing for a massive outbreak of killer flu this winter. Millions of people are expected to die worldwide as a new strain of super-bug sweeps the globe." In reality there was no flu pandemic anywhere. But the lack of any flu plague across the globe in 97 did not bring a halt to those 'killer flu' front-page specials and we were again treated with such a menu at the end of 2003, again with the same results.
The winters of 1998, 99, 2000, 01, 02, 03, saw the same, tired old headlines appearing in the press driving the public and herding them with fear into clinics to get their desperately needed flu shots. It does not take a lot of imagination to recognize this all as a long-term strategy leading up to the present recommendation by the ACIP to make flu vaccines universal and mandatory.
Our children face the possibility of death or serious long term adverse effects from mandated vaccines that aren't necessary or that have very limited benefits.
Jane M. Orient, M.D
The 1.55 trillion dollar health industry has Americans sick and suffering more than ever before. Not satisfied with their tremendous profits, the pharmaceutical makers want a vaccine program that targets everybody in the country to get vaccinated annually. At the same time, there is no mention of the accumulative side effects that such repeated shots would implicate. A flu vaccine program would require yearly inoculations due to the constantly changing strains of the disease. Advocates tell the public that such a program would reduce incidence of the disease and, quite possible, reduce fatalities. Saving lives is the ultimate selling point for the vaccine industry. Still, they hide the information clearly indicating how many people they are actually killing with their shots and how many more get injured.
"While the drug companies would like us to believe that these deaths are the unfortunate side effects of a careful and caring industry, they are actually the direct result of the ways in which pharmaceuticals manipulate drug trials and skew research data to produce the positive efficacy and safety results they need to bring new products to market," says Lynne Born health care activist, writer and independent medical researcher. Barbara Loe Fisher, president of the National Vaccination Information Center suggests extreme caution when moving toward the universal application of flu vaccines to all citizens because once instituted it will be very difficult for most Americans to avoid them.
"I think it is something that is going to happen, and I think it's something that is called for," says Len Novick, executive director of the National Foundation for Infectious Diseases (NFID). The Bethesda, Md., coalition represents private and public healthcare groups and industries, including drug manufacturers. The movement toward universal vaccination programs pumping toxic chemicals and biological compounds unnecessarily into the blood streams of the unsuspecting population serves only to pad the pockets of the pharmaceutical companies and their supporting groups that dictate and recommend public health policies all in the name of 'good'. Novick thinks it's good but there are doctors who claim that five consecutive flu shots will increase a persons chances of contracting Alzheimer's disease by a factor of ten because of the yearly build up of mercury that is contained in some flu vaccines.
The marketplace for the Pharmaceutical Giants is the ever-trusting public that believe that any recommendations handed down through the medical system are reliable and must be 'for our own good'. Agencies such as the NFID and The Advisory Committee on Immunization are continuously looking for new applications for the use of existing drugs and vaccines already on the market, as well as the creation of new designer drugs that earn them billions. The Advisory Committee on Immunization sits at the very center of a drug cartel that operates in every nation and they zealously guard the sanctity of vaccines so as not to cast serious doubt on modern medicine as a whole. To do so would destroy the empire that they have so carefully structured and the image of allopathic medicine would forever be shattered.
Many people today believe that the integrity of the medical cartel, at the highest level is suspect and serves to harm, weaken and ultimately destroy the very people it claims to protect. To weaken the immune system and interfere with the brain's ability to function optimally serves only to strengthen the ever-growing health monopoly and their financial profits. The handwriting is already on the wall. If the forces opposed to the medical cartel do not form an alliance, we will see vastly increased use of vaccines and increasing penalties for those who seek to avoid them. This is a critical moment in medical history with implications for the whole human race.
"Thiomersal has no place in medicine. It should be banned for use in humans," says Dr Mark Geier. "These are our children."
The Advisory Committee on Immunization is one of the most dangerous, untrustworthy and all-powerful institutions of this century and they commonly ignore fine physicians like Dr. Geier. If they are unable to come clean about the catastrophic mercury problem in vaccines, which the flu vaccine does contain, what can we really say about this organization? You will get parallel organizations like The Department of Health pointing out that reviews by the Committee on the Safety of Medicines found no evidence of low doses of thiomersal impacting on childhood development and then drop into the intellectual medical gutter with statements like, "Thiomersal has been used in vaccines for over 60 years. It has played an important role in maintaining the safety of vaccines."
"There is no evidence that any influenza vaccine thus far developed is effective in preventing or mitigating any attack of influenza. The producers of these vaccines know that they are worthless, but they go on selling them, anyway."Fukuda from the CDC comments that universal flu vaccines could be up for a vote before the Center of Disease Control in October 2005 with its earliest use as a standard coming in 2006. This translates into about nearly 300 million doses a year, one for every man, women and child in the United States. Who knows, soon it might be against the law to get the flu, unless of course you are already vaccinated against it. The entire discussion about the flu and a mass vaccination against it is actually ridiculous for the same thing caught in July is called a bad cold. We must remember though that billions of dollars are involved so the chances are the powers that be will have their way. That is unless we can have a medical revolution happen before 2006. If not the last thing I would want is to be an American in 2006.
Mark Sircus Ac., OMD
See also related:
On Vaccine Efficacy:
Flu Experts: Vaccine Effectiveness 'not demonstrated'
CDC Knew: Mercury in Vaccines Induces Autism
The Avian Flu and Drugless Doctors
Pharma makers withhold suicide data in drug studies
Ninety-three Children Dead of Flu - Majority were vaccinated!
Medical system is leading cause of death and injury in US
Unbelieveable!! -- CDC Still Allows Mercury in Infant Flu Shots
Flu Vaccine Officially Recommended for Infants
CDC's unspoken acceptance of vaccine additive raises furor
Mercury : The Winged Messenger - Book on mercury and autism
Exercise Alternative to Flu Vaccine
Chiron Readying Vaccines For Next Flu Season
LA Times: '91 Memo Warned of Mercury in Shots
No Evidence Flu Vaccine Works in Kids, Study Finds
Found on the Alternative Medicine Forum, posted there by Donna:
Bayer made Rhogam that contained 35 mcg of mercury, Bayer in 2003 Petitioned OEHHA to take thimerosal/mercury off the list of reproductive toxins, After parents with disabled children filed lawsuits. [The EPA limit for INGESTING mercury is 6 mcg! Pregnant women continue to be INJECTED with 25 mcg of mercury via the flu vaccine!] What happens to these disabled children, Some require many diffrent medications just to survive.
Here is OEHHA reply to Bayer.above article URL:
Wasting Taxpayer Dollars On Worthless Vaccines
http://www.redflagsdaily.com/yazbak/2005_aug24.html Vaccinate Johnny To Protect Grammy — And Other Wild Ideas
By Red Flags Columnist, F. Edward Yazbak, MD
In the "Flu Vaccine Saga: The Latest Twist," (5) I reviewed the findings of a study by the National Institute of Allergy and Infectious Diseases (NIAID) that was published in the Archives of Internal Medicine. (6)
The NIAID researchers carefully and methodically estimated influenza-related deaths — and all deaths — among the elderly in the United States during 33 consecutive flu seasons between 1968 and 2001.
They noted that:
1. For people 85 and older, the mortality rate did not change throughout the 33 annual flu seasonsIn an interview, the lead author stated that the dramatic increase in vaccination coverage among the elderly should have led to a dramatic drop in flu deaths. "This is not what we found ... So the mortality benefits are probably very much overestimated," she said.
All this did not sit well with the CDC experts, who for 30 years had recommended yearly flu vaccination. They promptly disagreed with the NIAID findings in the press and cited the ever-popular "30,000 to 36,000 flu deaths" a year. (7)
The study's lead author stood her ground: The flu vaccine — if administered to the elderly — does not decrease the influenza mortality among them but if we were able to vaccinate 70 percent or more children of school age, then we would indirectly be protecting the elderly better than if they were vaccinated.
The CDC liked that idea a lot and reminded everyone that children and infants starting at the age of six months should receive yearly influenza vaccinations.
To secure even better protection of the elderly, the agency and HHS (the U.S. Department of Health and Human Services) also helped draft recent legislation (Federal Register: Aug. 15, 2005 Vol. 70, No. 156) that would requireall nursing homes receiving Medicaid or Medicare dollars to provide all residents with an annual flu vaccination unless such vaccination is contraindicated or specifically refused. (8)
[Note: Dr. Tenpenny is a recognized expert on the subject of possible health risks posed by vaccination. To find out more about Dr. Tenpenny, please visit http://www.nmaseminars.com.]
The major media outlets are escalating the push for the flu shot to near hysteria, especially since the Centers for Disease Control and Prevention (CDC) announced that the flu vaccines "may" provide some protection against the A/Fujian strain. With the supply of flu vaccine running out, there is now new media-produced promotion for FluMist, the nasal spray flu vaccine. However, what is not being explored is the possibility that cases of flu may be caused by FluMist. An overview of the CDC's most recently available data regarding flu virus testing brings this question to the forefront.
Viral types and "antigenic drift"
Each year, the CDC incorporates antigens from the three major strains in circulation: an Influenza A-type strain from the H1N1 subtype; a second Influenza A-type strain from the H3N2 subtype; and a third virus from the Influenza-B strain.
Influenza B viruses circulate widely only among humans and are not divided into subtypes. Influenza B is known to be the cause of sporadic outbreaks of illness, especially in residential communities such as nursing homes.
The Influenza A strains are the most common cause of annual, widespread influenza outbreaks. Influenza A viruses are divided into subtypes based on the type of protein located on the surface of the virus. There are many subtypes of Influenza A viruses and some of these viruses can be found in animals, including ducks, chickens, pigs, whales, horses, and seals. Although unusual, an Influenza A type of virus from an animal can be transmitted to people.
The Influenza A subtypes most commonly found in people are (H1N1) and (H3N2) A virus from each of these subtype strains is selected each year for inclusion in the flu vaccines. The specific viral strains selected for this year's flu vaccines are A/New
Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and Hong Kong/1434/2002 (Type B). Both Fluzone and FluMist are made to protect against these three viruses. [2,3].
Influenza viruses can change in two different ways. One way is called "antigenic drift." These are small changes in the proteins on the surface of the virus that happen over time. Antigenic drift produces new viral strains. The new strains may not be recognized by a person's antibodies developed from a previous flu episode, or by antibodies induced by a previously given flu shot. This is the reason why new viruses are selected each year to correspond with viruses thought to be commonly circulating.
The other way that flu viruses can change is by a mechanism referred to as "antigenic shift." Antigenic shift is an abrupt, major change in the influenza A viruses, resulting in a completely new influenza A subtype. While influenza A viruses morph via antigenic drift all the time, antigenic shift happens only occasionally.
The CDC has announced that the viral strain, A/Fujian/411/2002 (H3N2) is the most prevalent virus being identified in the community setting. The A/Fujian strain was the predominate virus in Australia and New Zealand during the recent Southern Hemisphere influenza season and is a classified as a "drift variant" related to the A/Panama virus found in this year's vaccines. Because they are antigenically "related", antibodies produced against the A/Panama virus will cross-react with the A/Fujian virus, but much less strongly.
Will the current vaccine protect against the A/Fujian strain? The CDC says that "vaccine effectiveness depends, in part, on the match between vaccine strains and circulating viruses and cannot be determined by laboratory testing." Despite a degree of effectiveness suggested by a laboratory testing, clinical effectiveness from the flu shot—or from FluMist—cannot be presumed, and neither should it be assured.
The CDC's Numbers
Since September 28, the WHO and NREVSS laboratories have tested a total of 19,469 specimens, finding 25.6% of these samples to be positive for influenza virus. Among the 4,992 samples identified to contain influenza viruses, 99.6% of the viruses were Influenza A (and 0.4% were influenza B viruses). The CDC serotyped 20.4% of the
Influenza A viruses (1016 samples) finding 99.9% of them to be Influenza A (H3N2) viruses.
When subtyping was performed on 157 of the 1016 viral samples, 45 (29%) were found to be antigenically similar to vaccine strain A/Panama, and 112 (71%) were found to be similar to the drift variant, A/Fujian. Of note, one sample contained an Influenza A virus that was similar to the vaccine strain A/New Caledonia/20/99.
Downplaying the numbers
The CDC performed identification on only a small number of samples that were isolated. In fact, of 4,992 positive samples, only 1016 were found to be Influenza (H3N2) viruses. What were the other serotypes?
In addition, only 3% (157) of the H3N2 viruses were identified as subtypes. This is an extraordinarily small test sample. Even though the A/Fujian strain has been found in 71% (112) of this sample, what is being downplayed is that nearly 30% of the viruses have been identified as "antigenically similar" to viruses found in FluZone and FluMist: 45 samples (29%) had A/Panama strain viruses and one sample had the A/New Caledonia virus.
What is of great concern it that the CDC has subtyped so few samples. What if 50% or 60% or 80% had been subtyped? Would more A/Panama and A/New Caledonia viruses have been found? Would further testing implicate FluMist as a source of influenza?
Does the A/Panama virus come directly from FluMist? Is it possible to use this technology to differentiate vaccine-type A/Panama flu virus from an A/Panama wild-type virus?
Technology is available to differentiate wild virus from vaccine virus. For example, when a case of acute flaccid paralysis is identified in a Third World Country, PCR testing is used to differentiate wild polio virus vs. vaccine-induced polio virus vs. other types of viruses known to cause paralysis. Why are we not using this technology to determine community-acquired influenza from vaccine-induced influenza?
In addition to "finding" these strains within the community, it is known that FluMist contains the viral strains identified by the CDC. The question that demands an answer is this: Is FluMist shedding live viruses and infecting others? Could this nasal spray vaccine be a cause of the flu that is spreading throughout regions of the U.S.?
 CDC. Influenza Viruses.
Copyright © 2003 by Sherri Tenpenny. All Rights Reserved
Flu Hype: Observations by Jon Rappoport
[Note: the following article is excerpted from recent postings that appeared on the website ttp://www.nomorefakenews.com, written and published by investigative journalist Jon Rappoport.]
The Fujian Flu Virus
Much has been said about the failure of the CDC to make sure there was a vaccine that protected against Fujian flu-although, as you know if you read this site [nomorefakenews.com], there are about seventeen lies hiding behind the first part of this sentence.
But it is interesting that they didn't create a vaccine they thought would work against Fujian, and one of the reasons appears to be: they couldn't isolate (find) it in the egg medium they use to manufacture vaccines.
Couldn't find it?
That always raises red flags. One of those flags is, how much Fujian virus are they actually finding in patients diagnosed with that brand of flu? How much? Is it actually just a tiny amount? Because if that is the case, they have absolutely no reason to connect the virus with human illness...
Of course, we are getting no reports about this issue in the press. But it was a key in discrediting the whole research approach to SARS and AIDS, to name two familiar areas I've been over a thousand times on these pages.
Not enough virus (or whatever is being called a virus) in patients to explain the onset of illness. Not enough virus to cause "a pinprick."
If Fujian is one of those situations, it's another straight hoax from the ground up. It's already a hoax, for reasons I'm describing in stories over the last few days. But this would add another dimension.
Flu Stats for the Record-Time Capsule
Despite all the official admonitions about not being able to count numbers of flu cases accurately, I do find something in an Associated Press (AP) piece, "Tenn. Reports First Death of Flu Season," dated December 9.
"Each year an average of 36,000 people die from the flu and another 114,000 are hospitalized."
Keep those figures in mind when this season is all over, and see what the honchos are saying.
I mean, 36,000 deaths every year is already a major figure, and you don't need any Fujian strain blah blah.
They are trying to make 2003 a highly unusual and highly virulent Media Event, and they are succeeding. But as for actual numbers of people dying? My feeling is, the reality is going to be far less intense than the lies they're telling.
Put it in the time capsule.
Flu Journalism Peaks Early
This is a big one. It's about how the major headlines and the panic and the hysteria conceal a quite different flu reality when you do nothing more than just read down into the body of the current mainstream articles.
Case in point. Newsday.com is running "Flu is Widespread'/State officials say cases up, but no evidence of epidemic." December 13.
Still, that word "widespread." That's a juicy one, yes?
It's all over. It's out of control. We don't where it's heading next.
In the body of the story, however, we find out what "widespread" really means. Lo and behold it's a technical term defined by the CDC. It means at least one case has been reported in at least half of the designated medical regions of the state, where "sentinel doctors" check blood samples from patients.
And so far, there are no influenza clusters in New York state.
Hmm. Well, how many cases of the dreaded Fujian strain have the doctors identified? Turns out they haven't broken it down that far. They only know it's type A, and A includes several strains, one of which is Fujian.
Aha. Yeah. Well. So these "widespread" cases of flu could be just the usual ordinary stuff.
There is more.
How many deaths from the flu have been reported in New York state this year?
I was just reading an AP piece dated December 9 out of Nashville about the flu in Tennessee. "An estimated 700 to 900 people in Tennessee are killed by the flu each season…"
That's the regular estimate every year.
The last time I looked, New York is a lot big/ger than Tennessee. NY is going to have to get after it if it hopes to make a real contribution to the fear and hysteria. I mean, this is December already, and no deaths so far in NY? Come on.
Makes a person think we're getting played, doesn't it?
Two items. First, I have a report from Las Vegas. A local news station there carried a story about a two-year-old baby who had the flu shot and died 12 hours later. In the next breath, the station ran a quick hitter about the need for everyone, old and young, to go find a flu shot and get it.
Item two: An AP story dated December 9. Nashville. "Tennessee has recorded its first death related to this flu season, and health officials say more problems could be on the way."
That's the lead. Then we get this: "An elderly Davidson County man with other health problems died last week from complications related to the flu..."
I see. Related to. Other health problems.
What other problems? Seventeen prior bouts of pneumonia? Was ingesting 40 medical drugs of an extremely toxic nature for ten years? He needed just one more event, a cough and a fever, to push him into death?
But they lead with this item because it hooks the reader in, and most people don't bother to think anyway. Much too taxing.
Flu Jive on Parade
Today AP has released a piece called "Flu Has Spread to All 50 States." The thrust of the article is hysteria, long lines at clinics, people unable to get a shot of the vaccine because of shortages.
For those who have a few working brain cells left, I want to quote several sentences buried in the story.
"The CDC said it is unable to know how many children typically die of the flu each year, making it unclear whether this is in fact a particularly lethal year." Boom.
No basis for comparison.
Then we get this beauty: "Flu and its complications are the sixth-leading cause of death nationally among children age 4 and younger, according to the CDC."
I thought the CDC was saying it didn't know how many children die of the flu every year.
"Yeah, well we don't know how many, but we know it's the sixth leading cause of death and don't ask how we know because we just do so shut up."
And finally: "Despite the severity of the early outbreak, health experts are not ready to predict just how bad the flu season will be. The season still may peak as early as December [that would be now], rather than February, which is the norm."
So when this is all over, the stats may be the same as any other year.
If they really have any idea what the stats are. And it looks like they don't.
Otherwise they're perfect.
And if the mad coverage in the press had been toned down, we might not have gotten all these long lines at vaccine clinics, we might not have gotten school closures, we might not have gotten as many people staying home from work.
Copyright © 2003 by Jon Rappoport and www.nomorefakenews.com. All rights reserved.
"posters.in the hospital requesting anyone who had FluMist within the past 21 days to leave the premises immediately..employees who take the shot are subject to 21 days mandatory suspension.insurance companies are refusing to reimburse..The main reason is the common `side-effects '.brain swelling"
FluMist Package Inserts:
Open letter to Pediatrician by Thomas Stone, MD